02 May 2019 – Destiny Pharma welcomes United Nations report

Destiny Pharma welcomes a United Nations report calling for immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis

Destiny Pharma’s XF drug platform is well positioned to address the report’s recommendation for more innovation to tackle antimicrobial resistance

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of antimicrobial resistance (AMR), welcomes a new report from the United Nations, and others, entitled ‘No time to wait: securing the future from drug-resistant infections’

The report underscores that AMR is a global crisis.  Unless the world acts urgently, AMR will have a disastrous impact within a generation, with the World Bank predicting 10 million deaths every year by 2050, if no action is taken.

One of the five key recommendations within the report is to ‘innovate to secure the future’, including the development of new antimicrobials.  Destiny Pharma’s targeted approach, through the development of an antibacterial platform, the XF drugs, whose novel bacterial membrane action has been shown to impede resistance development, is well positioned to address this recommendation.  The Company’s lead drug candidate, XF-73, is currently in Phase 2b development for the prevention of post-surgical hospital infections, with recruitment in the trial expected to complete later this year.

The full report can be found here.

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com